On Friday, the European Medicines Agency (EMA) warned patients using weight-loss drugs, such as Novo Nordisk A/S’s (NYSE:NVO) Wegovy, to inform their doctors before general anesthesia or deep sedation surgery. This recommendation stems from potential respiratory complications linked to these medications. Related: Only 25% Patients Stick With Novo Nordisk’s Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient. Weight-loss drugs like Wegovy and Eli Lilly And Co’s (NYSE:LLY) Zepbound and Mounjaro belong to a class known as GLP-1 receptor agonists, which slow the emptying ...